免疫突触:T细胞与肿瘤细胞“死亡之吻”

  • A+
所属分类:EGFR基因突变
什么是免疫突触
免疫突触是抗原呈递细胞或靶细胞与淋巴细胞(如T / B细胞或自然杀伤细胞)之间的互动界面。免疫突触由参与T细胞活化的分子组成,其组成典型的功能结构-激活簇。
T细胞与APC表面粘附分子之间通过受体-配体相互作用得以紧密接触,形成了一个瞬时性结构,该结构以TCR-MHC-抗原肽三元结构为簇状中心,周围环形分布着粘附分子。这一结构的形成有助于T细胞分辨潜在的抗原,提高了TCR与MHC-抗原肽复合物之间的亲和力,从而启动了T细胞的抗原识别和活化,有研究表明,只有形成免疫突触的T细胞才能发生增殖。
基因突变检测
Nele M. G. Dieckmann, Gordon L. Frazer, Yukako Asano, Jane C. Stinchcombe and Gillian M. Griffiths* The cytotoxic T lymphocyte immune synapse at a glance. Journal of Cell Science (2016) 129, 2881-2886

可观看视频(From Wikipedia, the free encyclopedia)T细胞(绿)与B细胞间形成免疫突触

免疫突触:T细胞与肿瘤细胞“死亡之吻”
 

免疫突触也称为超分子激活簇或SMAC。[3]这种结构由同心环组成,每个环含有分离的蛋白质簇-通常称为免疫突触的靶心模型,即典型的Bull’s-eye结构。

 

在1998年的一篇发表于Nature的《three-dimensionalsegregation of supramolecular activation clusters in T cells》中首次描述了其3D结构。

C-SMAC(中央-SMAC):蛋白激酶C,[4] CD2,CD4,CD8,CD28,Lck,和Fyn。[5]

p-SMAC(外周-SMAC),其中淋巴细胞功能相关抗原-1(LFA-1)和细胞骨架蛋白talin聚集在其中。[3]

d-SMAC(远端-SMAC)富含CD43和CD45分子。[6] [7]

 

免疫突触:T细胞与肿瘤细胞“死亡之吻”
免疫突触形成过程中的关键事件。Top,图表示T细胞(左)与抗原呈递细胞(APC)产生粘附(右),以及早期形成的离散域,中心超分子激活簇(cSMAC)(红色)含有T细胞受体( TCR)/ CD3复合物和信号蛋白,及其外周SMAC(pSMAC)的整合素和配体蛋白(蓝色)。左下栏,辅助T细胞(TH)与专职APC细胞 (表达MHC-II)形成免疫突触,包括F-肌动蛋白聚集(顶部,红色)和分泌设备(绿色)和微管中心化(底部,在黑色中),导致外泌体 exosome(亮绿色球体)的极化分泌和细胞因子(星形)的非极化分泌。右下方列,CD8 + T(CTL)突触中的事件,包括F-肌动蛋白积聚和分泌区域的形成(顶部)和分泌装置(紫色)和微管中心化(底部,黑色),导致裂解颗粒的高度极化分泌,杀死靶细胞。

 

Overview of the spatiotemporal events of the IS

The study of the IS has focused on the establishment of hierarchical, spatiotemporally segregated events during the contact between the APC and the T cell. These events include the following:

1) Establishment of low-affinity, exploratory contacts between the T cell and the APC

2) Initial, scattered contact of the TCR with the antigenloaded MHC on the APC, followed by initiation of TCRdependent signaling pathways upon specific recognition of

the MHC-peptide complex. Such activation is “umbrella shaped” (simultaneous activation and amplification of multiple pathways through different sets of effectors) and induces the activation of multiple effectors, including  membrane-bound molecules, e.g. integrins, signaling adaptors, cytoskeletal elements, and transcription factors

3) Transactivation of adhesion molecules (integrins) that consolidate the interaction between the T cell and the APC.

This step actually begins after initial TCR activation (step 2), but they evolve in parallel

4) Cytoskeleton- and signaling-dependent clustering of adhesion molecules and the TCR/CD3 complex at the contact interface between the T cell and the APC. In most cases, clustering is spatiotemporally segregated, i.e. the TCR/CD3 clusters and the integrin clusters, and their respective sets of adaptors, are separated

5) Signaling- and motor-dependent positioning of the secretory apparatus (including microtubules and microtubule-binding proteins) to the contact interface of the T cell

6) (Primed CTL only, also natural killer [NK] cells) Actin clearance at the center of the contact interface, enabling a tight association of the secretory apparatus with the plasma membrane

7-i) (TH cells) Stabilization of the contact and transcriptional activation of the T cell, including cytokine production and the expression of activation markers

7-ii) (Naïve CTL) Stabilization of the contact, priming and activation

7-iii) (Primed CTL and NK cells) Degranulation and target cell killing

8) Termination of the contact

 

免疫突触:T细胞与肿瘤细胞“死亡之吻”
新的研究提示,并不是所有的免疫突触中,都存在这种典型的“bull‘s eye’ 结构。上图中显示了不同免疫细胞相互接触形成不同的免疫突触形态。为了弄清楚这种细胞间的接触交流会受到不同形态的免疫突触的影响存在哪些更复杂的机制,需要更多的研究。

需要注意的是,这张图示来自于不同研究的总结,可能受到不同的研究方法和途径的影响。

 

免疫突触的功能
The immunological synapse (IS) can have several functions, with varying importance for particular cell–cell interactions

免疫突触:T细胞与肿瘤细胞“死亡之吻”
Daniel M. Davis1 and Michael L. Dustin2 What is the importance of the immunological synapse?

简而言之:这确保了细胞毒性组分穿孔素和颗粒酶的精确分泌,并且还可能介导于细胞死亡介质FasL的定向递送。(Bossi and Griffiths, 1999; Kägi et al., 1994;Stinchcombe et al., 2006; Tschopp and Nabholz, 1990).

concluding remarks:towards the application of manipulating the IS in biomedicine

基因突变检测
免疫突触的形成和功能,具有更多未被发现和描述的复杂机制,现代肿瘤免疫学的进步让我们可以用浅显的视角管中窥豹,一些旨在加强免疫突触形成,以增强PD-1/L1抑制剂参与的T细胞介导的肿瘤免疫治疗策略正在临床研究阶段。

 

发表评论

您必须登录才能发表评论!